Results 211 to 220 of about 23,536 (264)

Design Strategies of Novel NNRTIs to Overcome Drug Resistance

Current Medicinal Chemistry, 2009
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are very potent and most promising anti-AIDS drugs that specifically inhibit HIV-1 reverse transcriptase (RT). However, to a great extent, the efficacy of NNRTI drugs is impaired by rapid emergence of drug-resistance mutations.
Peng, Zhan, Xinyong, Liu, Zhenyu, Li, Christophe, Pannecouque, Erik, De Clercq   +4 more
openaire   +2 more sources

The role of NNRTIs in antiretroviral combination therapy: An introduction

International Journal of STD & AIDS, 2001
In October 2000 a meeting was convened by DuPont Pharma in Scotland to discuss the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiretroviral therapy. The Round Table meeting focused on comparisons between efavirenz and nevirapine in clinical studies and clinical practice, and the manuscripts published in this supplement report ...
openaire   +2 more sources

Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy

Antiviral Therapy, 2003
Objective To assess the prevalence of modest (<10-fold) decreases in baseline non-nucleoside reverse transcriptase inhibitor (NNRTI) susceptibility and their impact on virological response to NNRTI-containing triple therapy in drug-naive individuals ...
P Richard, Harrigan, Kurt, Hertogs, Werner, Verbiest, Brendan, Larder, Benita, Yip, Zabrina L, Brumme, Christopher, Alexander, Jessica, Tilley, Michael V, O'Shaughnessy, Julio S G, Montaner   +9 more
openaire   +2 more sources

Sulfanyltriazole/tetrazoles: A Promising Class of HIV-1 NNRTIs

Mini-Reviews in Medicinal Chemistry, 2009
There is an urgent need for the design and development of new and safer drugs for the treatment of human immunodeficiency virus (HIV) infection, specifically active against drug-resistant viral strains. Recently, sulfanyltriazole/tetrazole derivatives were reported as potent HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs), with low ...
Peng, Zhan, Zhenyu, Li, Xinyong, Liu, Erik, De Clercq   +3 more
openaire   +2 more sources

A Concise and Selective Synthesis of Novel 5-Aryloxyimidazole NNRTIs

Organic Letters, 2006
[reaction: see text] A concise and efficient route to the construction of a 5-aryloxyimidazole has been developed. The key step was the selective O-arylation of a 2,4-dimethoxybenzyl-protected imidazolone. The final compound is a potent inhibitor of HIV reverse transcriptase.
Lyn H, Jones, Thomas, Dupont, Charles E, Mowbray, Sandra D, Newman   +3 more
openaire   +2 more sources

Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket

European Journal of Medicinal Chemistry, 2016
On the basis of structure-based bioisosteric replacement and molecular hybridization strategy, a series of novel dual structural-conformation inhibitors targeting the "entrance channel" of HIV-1 NNRTIs binding pocket (NNIBP) were designed and synthesized.
Qing, Meng, Xuwang, Chen, Dongwei, Kang, Boshi, Huang, Wenxin, Li, Peng, Zhan, Dirk, Daelemans, Erik, De Clercq, Christophe, Pannecouque, Xinyong, Liu   +9 more
openaire   +2 more sources

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

2013
HIV is a retrovirus; the retroviral life cycle is characterized by two specific steps: (1) the conversion of the single-stranded RNA genome found in the virion into double-stranded DNA by the viral enzyme reverse transcriptase (RT) and (2) the subsequent insertion of this DNA copy into the host genome by the viral enzyme integrase.
Kalyan Das, Eddy Arnold, Stephen H. Hughes   +2 more
openaire   +1 more source

Neuer NNRTI zugelassen

MMW - Fortschritte der Medizin, 2019
  +4 more sources

Review of NNRTIs: 'today and tomorrow'.

International journal of clinical practice. Supplement, 2000
Since 1996 indinavir in combination with zidovudine + lamivudine has been the standard regimen in the treatment of HIV infection. Although protease inhibitor (PI) containing therapies are very potent, many problems have now been identified that reduce quality of life such as a high pill burden, multiple daily dosing and dietary constraints. In addition,
openaire   +1 more source

HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa

Journal of Antimicrobial Chemotherapy, 2017
K. Steegen, M. Bronze, M. Papathanasopoulos, G. V. van Zyl, D. Goedhals, E. Variava, W. Macleod, I. Sanne, W. Stevens, S. Carmona   +9 more
semanticscholar   +1 more source